Company: ARVN
Filing Date: 2025-04-28
Form Type: 8-K
Source: 0001655759-25-000069
Chunk: 0

Company: ARVINAS, INC.
Filing Date: 2025-04-28
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On April 28, 2025, Arvinas, Inc. (the “ Company”), presented data from preclinical combination studies of ARV-393, the Company’s investigational PROteolysis TArgeting Chimera (“ PROTAC”) B-cell lymphoma 6 protein (“ BCL6”) degrader. The results from these preclinical studies were shared in a poster presentation at the 2025 American Association for Cancer Research (“ AACR”) annual meeting in Chicago, Illinois.

The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.